BIOMAT Database Logo BIOMAT Database Logo

[Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in neonates and young infants]. 1988

H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
Department of Pediatrics, Asahikawa Medical College.

Twenty three neonates and young infants were treated with imipenem/cilastatin sodium (IPM/CS) and its clinical efficacy and side effects were evaluated. Ages of the patients ranged from 0 to 83 days, and their body weights ranged from 750 to 4,760 g. Doses of IPM/CS ranged from 17.4 to 21.5 mg/kg as IPM every 6 to 12 hours for 3 to 12 days. Sixteen patients with infections including sepsis, meningitis and pneumonia, appeared to have responded to the IPM/CS treatment. Among them, clinical results were excellent in 2, good in 12 and fair in 2 patients. The drug was well tolerated, but 1 patient had diarrhea, 1 had redness of body during infusion, 1 had elevated GOT and GPT, and 2 patients showed only elevated values of GOT only among the 23 patients. The pharmacokinetics of IPM/CS were studied in 7 patients. Their ages ranged from 0 to 9 days, and body weights ranged from 2.5 to 4.0 kg. Serum concentrations of IPM were between 18.0 and 96.9 micrograms/ml and those of CS ranged 31.7 and 144.5 micrograms/ml in 6 patients at the end of intravenous drip infusion 20 mg/20 mg/kg during 30 or 60 minutes. Elimination half-lives of IPM ranged from 1.2 to 2.0 hours, and those of CS ranged from 1.4 to 2.7 hours. Serum concentrations of IPM was 14.7 micrograms/ml and that of CS was 32.4 micrograms/ml in 1 patient at the end of 30 minute-drip infusion 10 mg/10 mg/kg. The elimination half-lives of IPM was 1.5 hours, and that of CS was 2.9 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants].
May 1989, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants].
November 1988, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group].
April 1989, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates].
November 1988, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
May 1989, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
May 1989, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates.
January 1987, Scandinavian journal of infectious diseases. Supplementum,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants].
November 1988, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetics and clinical efficacy of imipenem/cilastatin sodium in neonates].
November 1988, The Japanese journal of antibiotics,
H Sakata, and H Kakehashi, and K Fujita, and K Murono, and M Kaeriyama, and T Oka, and H Yoshioka, and N Sasaki, and Y Mori, and S Maruyama
[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium].
July 1986, The Japanese journal of antibiotics,
Copied contents to your clipboard!